Century Therapeutics Inc Total Liabilities
Century Therapeutics Inc total liabilities. Based on the latest financial reports, Century Therapeutics Inc (IPSC) has total liabilities worth $54.66 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IPSC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Century Therapeutics Inc (2015–2025)
Total liabilities of Century Therapeutics Inc from 2015 to 2025. This chart illustrates how Century Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Century Therapeutics Inc (IPSC) investment intensity to see how much of total assets are deployed in long-term investments.
Century Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Century Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianjin Hi-Tech Development Co Ltd
SHG:600082
|
China | CN¥844.47 Million |
|
Beijing Airport High-Tech Park Co Ltd
SHG:600463
|
China | CN¥1.71 Billion |
|
WONIK Materials Co.Ltd
KQ:104830
|
Korea | ₩125.53 Billion |
|
Sky Harbour Group Corp
NYSE MKT:SKYH
|
USA | $357.28 Million |
|
Cantor Equity Partners II, Inc.
NASDAQ:CEPT
|
USA | $6.13 Million |
|
Eaton Vance Senior Floating Rate Closed Fund
NYSE:EFR
|
USA | $104.27 Million |
|
Sunny Friend Environmental Technology Co Ltd
TW:8341
|
Taiwan | NT$4.71 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Century Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Century Therapeutics Inc's balance sheet.
Liquidity & Leverage Metrics
Century Therapeutics Inc Total Liabilities Ratios Explained
Century Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Century Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Century Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of Century Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $64.77 Million | -66.24% |
| 2024-12-31 | $191.85 Million | +9.04% |
| 2023-12-31 | $175.94 Million | -4.28% |
| 2022-12-31 | $183.81 Million | +346.81% |
| 2021-12-31 | $41.14 Million | -80.70% |
| 2020-12-31 | $213.19 Million | +16.65% |
| 2019-12-31 | $182.75 Million | -68.25% |
| 2016-12-31 | $575.54 Million | +18.67% |
| 2015-12-31 | $484.99 Million | -- |
About Century Therapeutics Inc
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the deve… Read more